108 related articles for article (PubMed ID: 24824064)
21. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.
Olsson RI; Jacobson I; Boström J; Fex T; Björe A; Olsson C; Sundell J; Gran U; Öhrn A; Nordin A; Gyll J; Thorstensson M; Hayen A; Aplander K; Hidestål O; Jiang F; Linhardt G; Forsström E; Collins T; Sundqvist M; Lindhardt E; Åstrand A; Löfberg B
Bioorg Med Chem Lett; 2013 Feb; 23(3):706-10. PubMed ID: 23260347
[TBL] [Abstract][Full Text] [Related]
23. Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5.
Zhao Z; Ruan S; Ma X; Feng Q; Xie Z; Nie Z; Fan P; Qian M; He X; Wu S; Zhang Y; Zheng X
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861703
[TBL] [Abstract][Full Text] [Related]
24. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
25. [Effects of ethanol on action potential of rat myocardium and human Kv1.5 channel].
Hu H; Zhou J; Sun Q; Yu XJ; Zhang HL; Ma X; Liu CH; Zang WJ
Sheng Li Xue Bao; 2011 Jun; 63(3):219-24. PubMed ID: 21681339
[TBL] [Abstract][Full Text] [Related]
26. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
27. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
Ford J; Milnes J; Wettwer E; Christ T; Rogers M; Sutton K; Madge D; Virag L; Jost N; Horvath Z; Matschke K; Varro A; Ravens U
J Cardiovasc Pharmacol; 2013 May; 61(5):408-15. PubMed ID: 23364608
[TBL] [Abstract][Full Text] [Related]
28. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
29. Pseudosaccharin amines as potent and selective KV1.5 blockers.
Lloyd J; Finlay HJ; Kover A; Johnson J; Pi Z; Jiang J; Neels J; Cavallaro C; Wexler R; Conder ML; Shi H; Li D; Sun H; Chimalakonda A; Huang C; Salvati M; Levesque P
Bioorg Med Chem Lett; 2015 Nov; 25(21):4983-4986. PubMed ID: 25801931
[TBL] [Abstract][Full Text] [Related]
30. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
31. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
32. Structure-based virtual screening and electrophysiological evaluation of new chemotypes of K(v)1.5 channel blockers.
Yang Q; Fedida D; Xu H; Wang B; Du L; Wang X; Li M; You Q
ChemMedChem; 2010 Aug; 5(8):1353-8. PubMed ID: 20540065
[TBL] [Abstract][Full Text] [Related]
33. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
34. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
35. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
[TBL] [Abstract][Full Text] [Related]
36. Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.
Wolkenberg SE; Nolt MB; Bilodeau MT; Trotter BW; Manley PJ; Kett NR; Nanda KK; Wu Z; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Dinsmore CJ; Lindsley CW; Hartman GD
Bioorg Med Chem Lett; 2017 Feb; 27(4):1062-1069. PubMed ID: 28131713
[TBL] [Abstract][Full Text] [Related]
37. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation.
Christophersen IE; Olesen MS; Liang B; Andersen MN; Larsen AP; Nielsen JB; Haunsø S; Olesen SP; Tveit A; Svendsen JH; Schmitt N
Eur Heart J; 2013 May; 34(20):1517-25. PubMed ID: 23264583
[TBL] [Abstract][Full Text] [Related]
38. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
Wu S; Fluxe A; Janusz JM; Sheffer JB; Browning G; Blass B; Cobum K; Hedges R; Murawsky M; Fang B; Fadayel GM; Hare M; Djandjighian L
Bioorg Med Chem Lett; 2006 Nov; 16(22):5859-63. PubMed ID: 16942874
[TBL] [Abstract][Full Text] [Related]
39. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
